Economic evaluation of sequences of biological treatments for patients with moderate-to-severe Rheumatoid Arthritis and inadequate response or intolerance to Methotrexate in France
An economic evaluation for France of bDMARD sequences for treatment of moderate-to-severe RA after inadequate response or intolerance to conventional DMARDs (eg, methotrexate).
This project has received funding from the European Union’s Horizon 2020
Economic evaluation of sequences of biological treatments for patients with moderate-to-severe Rheumatoid Arthritis and inadequate response or intolerance to Methotrexate in France
An economic evaluation for France of bDMARD sequences for treatment of moderate-to-severe RA after inadequate response or intolerance to conventional DMARDs (eg, methotrexate).
Attached Files